Bengaluru Counterfeit Medicine Bust Highlights India's Regulatory Crisis

Gist The unearthing of a massive counterfeit medicine racket in Bengaluru has exposed critical vulnerabilities in India's pharmaceutical supply chain and drug regulatory mechanisms. Authorities discovered an illicit operation where expired and fake life-saving medicines were repackaged and sold to numerous hospitals, directly endangering patient safety. This incident highlights severe systemic gaps in quality control that not only threaten domestic public health but also repeatedly jeopardize India's global ambition to serve as the 'pharmacy of the world'. Aspirants must understand the regulatory failures that allow spurious drug networks to thrive and the consequent impact on health governance. Background India actively promotes itself as the 'pharmacy of the world' and heavily leverages the Make in India campaign to boost pharmaceutical manufacturing and exports. Despite its high production volume, the country's drug regulatory framework historically struggles to implement adequate monitoring and stringent quality control systems. The system's fragility was recently highlighted on a global scale when Indian-manufactured contaminated cough syrups were linked to international fatalities, severely denting the country's manufacturing credibility. Prior to this bust, an unchecked distribution mechanism allowed unverified, heavily…